Hyderabad, April 13, 2015
Dr Reddy’s Laboratories and its subsidiary, Promius Pharma today announced filing of three new drug applications (NDAs) with the US Food and Drug Administration.
Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid, the company said in a filing to the BSE today.
Raghav Chari, Executive Vice President of Proprietary Products at Dr Reddy’s and President of Primus Pharma said “These products represent new, compelling options for segments of patients suffering from Psoriasis, Rosacea and Migraine”.
They are also the first of a large basket of products targeting conditions predominantly treated by dermatologist and neurologists. Upon approval, the products will be commercialised by Promius Pharma.
